Cometriq (Cabozantinib S-Malate) Patent Expiration, LOE Window & CMS Spending
Cometriq (Cabozantinib S-Malate) by Exelixis: FDA Orange Book core substance LOE 2030-10-08 (last listed 2032-02-10), 1 AB generics, $4.0M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Exelixis |
| FDA Application & Pathway | N203756 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-10-08 |
| Last Listed Patent or Exclusivity Date | 2032-02-10 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $4.0M |
| 2024 Medicare Part D Spend | $3.3M |
| 2024 Medicaid Spend | $696K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Exelixis across sibling Meru public-data platforms.